Protagonist Therapeutics Stock Fundamentals
| PTGX Stock | USD 36.15 1.06 3.02% |
Protagonist Therapeutics fundamentals help investors to digest information that contributes to Protagonist Therapeutics' financial success or failures. It also enables traders to predict the movement of Protagonist Stock. The fundamental analysis module provides a way to measure Protagonist Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protagonist Therapeutics stock.
At this time, Protagonist Therapeutics' Net Income is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 4.4 M in 2025, whereas Other Operating Expenses is likely to drop slightly above 90.9 M in 2025. Protagonist | Select Account or Indicator |
Protagonist Therapeutics Company Return On Equity Analysis
Protagonist Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Protagonist Therapeutics Return On Equity | 0.54 |
Most of Protagonist Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protagonist Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Protagonist Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Protagonist Therapeutics has a Return On Equity of 0.5439. This is 102.27% lower than that of the Biotechnology sector and 101.49% lower than that of the Health Care industry. The return on equity for all United States stocks is notably lower than that of the firm.
Protagonist Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Protagonist Therapeutics's current stock value. Our valuation model uses many indicators to compare Protagonist Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Protagonist Therapeutics competition to find correlations between indicators driving Protagonist Therapeutics's intrinsic value. More Info.Protagonist Therapeutics is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.53 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Protagonist Therapeutics is roughly 1.90 . At this time, Protagonist Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Protagonist Therapeutics' earnings, one of the primary drivers of an investment's value.Protagonist Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protagonist Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protagonist Therapeutics could also be used in its relative valuation, which is a method of valuing Protagonist Therapeutics by comparing valuation metrics of similar companies.Protagonist Therapeutics is currently under evaluation in return on equity category among its peers.
Protagonist Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Protagonist Therapeutics from analyzing Protagonist Therapeutics' financial statements. These drivers represent accounts that assess Protagonist Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Protagonist Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 693.4M | 1.6B | 535.1M | 1.3B | 2.4B | 2.5B | |
| Enterprise Value | 582.0M | 1.5B | 413.0M | 1.1B | 2.3B | 2.4B |
Protagonist Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Protagonist Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Protagonist Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Protagonist Fundamentals
| Return On Equity | 0.54 | ||||
| Return On Asset | 0.29 | ||||
| Profit Margin | 0.63 % | ||||
| Operating Margin | 0.74 % | ||||
| Current Valuation | 1.75 B | ||||
| Shares Outstanding | 61.38 M | ||||
| Shares Owned By Insiders | 1.84 % | ||||
| Shares Owned By Institutions | 99.00 % | ||||
| Number Of Shares Shorted | 3.79 M | ||||
| Price To Earning | (4.81) X | ||||
| Price To Book | 3.19 X | ||||
| Price To Sales | 4.96 X | ||||
| Revenue | 434.43 M | ||||
| Gross Profit | 434.43 M | ||||
| EBITDA | 252.84 M | ||||
| Net Income | 275.19 M | ||||
| Cash And Equivalents | 291.89 M | ||||
| Cash Per Share | 5.95 X | ||||
| Total Debt | 10.87 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 7.59 X | ||||
| Book Value Per Share | 11.06 X | ||||
| Cash Flow From Operations | 184.15 M | ||||
| Short Ratio | 6.91 X | ||||
| Earnings Per Share | 4.23 X | ||||
| Target Price | 58.3 | ||||
| Beta | 2.21 | ||||
| Market Capitalization | 2.15 B | ||||
| Total Asset | 744.73 M | ||||
| Retained Earnings | (340.52 M) | ||||
| Working Capital | 544.24 M | ||||
| Current Asset | 83.24 M | ||||
| Current Liabilities | 6.43 M | ||||
| Net Asset | 744.73 M |
About Protagonist Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagonist Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagonist Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagonist Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 18.9 M | 11.7 M | |
| Total Revenue | 434.4 M | 456.2 M | |
| Cost Of Revenue | 3 M | 2.8 M | |
| Stock Based Compensation To Revenue | 0.56 | 0.53 | |
| Sales General And Administrative To Revenue | 0.64 | 0.61 | |
| Research And Ddevelopement To Revenue | 2.30 | 2.19 | |
| Capex To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 1.22 | 0.87 | |
| Ebit Per Revenue | (1.40) | (1.48) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.